Scientists at Mayo Foundation for Medical Education and Research (MFMER) and Sanford Burnham Prebys Medical Discovery Institute have described G-protein coupled bile acid receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) antagonists reported to be useful for the treatment of cancer and polycystic liver.
Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick disease, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and diabetic neuropathy, among others.
City of Hope has disclosed proliferating cell nuclear antigen (PCNA) inhibitors acting as apoptosis inducers reported to be useful for the treatment of cancer.
Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.
Researchers at Cimplrx Co. Ltd. and Samjin Pharmaceutical Co. Ltd. have identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, hypophosphatemia, osteoarthritis, cystic fibrosis, type 2 diabetes, Alzheimer’s disease, and viral and bacterial infections.
Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic neuritis and Guillain-Barré syndrome.
Scientists at Beijing Wehand-Bio Pharmaceutical Co. Ltd. and Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have synthesized phthalazinone compounds with neuroprotective effects reported to be useful for the treatment of hemorrhagic and ischemic stroke.
Syndax Pharmaceuticals Inc. has disclosed extended purine tricyclic and bicyclic nucleosides as prodrugs reported to be useful for the treatment of viral infections.
RSS